Coronavirus Update: Gilead To Meet Global Remdesivir Demand By October
Plus: AstraZeneca Signs China Vaccine Deal
Ramp-up is possible thanks to increased internal capacity and network of voluntary licensing partners including Mylan, Cipla and Dr Reddy's.
You may also be interested in...
Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.
Keeping Track: Veklury NDA Arrives At US FDA; Olinvyk Sees Approval; MAb Filings By Regneron, Y-mAbs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.